Stock Fundamentals

Company Information

Company Name
Prelude Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US74065P1012
CIK: 0001678660
CUSIP: 74065P101
Currency: USD
Full Time Employees: 79
Phone: 302 467 1280
Fiscal Year End: December
IPO Date: Sep 25, 2020
Description:

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Address:

175 Innovation Boulevard, Wilmington, DE, United States, 19805

Directors & Officers

Name Title Year Born
Dr. Krishna Vaddi D.V.M., Ph.D. Founder, CEO & Director 1966
Mr. Bryant David Lim J.D. CFO, Chief Legal Officer & Corporate Secretary 1971
Dr. Peggy A. Scherle Ph.D. Chief Scientific Officer 1962
Ms. Aimee Crombie Ph.D. Senior VP and Head of Strategic Planning & Operations NA
Dr. Madhu Pudipeddi Ph.D. Senior Vice President of Technical Operations NA
Mr. Robert A. Doody Jr. Senior Vice President of Investor Relations NA
Ms. Michele Porreca M.B.A. Chief People Officer NA
Dr. Andrew P. Combs Ph.D. Executive VP & Chief Chemistry Officer 1967
Mr. Naveen Babbar Ph.D. Senior Vice President of Translation Medicine NA
Dr. Wan-Jen Hong M.D. Senior Vice President of Clinical Development 1979

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 21, 2026 David P Bonita N/A Purchase 2.82M $4.44 $12.50M
Apr 21, 2026 Orbimed Advisors Llc N/A Purchase 2.82M $4.44 $12.50M

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Orbimed Advisors, LLC 10.91M Mar 31, 2026 17.31% $0.74 0.00%
Baker Bros Advisors LP 10.12M Mar 31, 2026 16.06% $0.20 0.00%
Kynam Capital Management, LP 1.59M Mar 31, 2026 2.53% $0.34 101.88%
Vanguard Group Inc 1.41M Dec 31, 2025 2.24% $0.00 42.42%
EcoR1 Capital, LLC 947.05K Mar 31, 2026 1.50% $0.14 0.00%
Two Sigma Investments LLC 923.63K Mar 31, 2026 1.47% $0.00 17.11%
Sphera Funds Management Ltd. 558.34K Mar 31, 2026 0.89% $0.30 354.85%
Acadian Asset Management LLC 511.52K Mar 31, 2026 0.81% $0.00 0.00%
Millennium Management LLC 382.74K Mar 31, 2026 0.61% $0.00 153.47%
Marshall Wace Asset Management Ltd 358.91K Mar 31, 2026 0.57% $0.00 31.04%
Morgan Stanley - Brokerage Accounts 322.16K Mar 31, 2026 0.51% $0.00 -3.81%
BlackRock Inc 321.89K Mar 31, 2026 0.51% $0.00 20.88%
Geode Capital Management, LLC 302.46K Mar 31, 2026 0.48% $0.00 10.84%
Renaissance Technologies Corp 275.20K Mar 31, 2026 0.44% $0.00 1.44%
Susquehanna International Group, LLP 267.79K Mar 31, 2026 0.42% $0.00 97.03%
Two Sigma Advisers, LLC 237.30K Dec 31, 2025 0.38% $0.00 6.56%
The Goldman Sachs Group Inc 236.47K Mar 31, 2026 0.38% $0.00 101.29%
Jane Street Group LLC 192.96K Mar 31, 2026 0.31% $0.00 73.78%
ADAR1 Capital Management LLC 152.83K Mar 31, 2026 0.24% $0.03 0.00%
State Street Corp 138.23K Mar 31, 2026 0.22% $0.00 8.59%

Shares Statistics

Shares Outstanding: 64.92M
Shares Float: 27.59M
% Insiders: 1,379.60%
% Institutions: 6,432.40%
Short % Float: 7.36%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 936.00K 1.49% ▲ 0.00% Apr 30, 2026
2 Biotech Growth Ord 346.50K 0.55% ▲ 0.00% Feb 28, 2026
3 Vanguard Institutional Extnd Mkt Idx Tr 276.97K 0.44% ▲ 5.25% Apr 30, 2026
4 Fidelity Extended Market Index 135.65K 0.22% ▲ 3.82% Mar 31, 2026
5 Blackrock Extended Mkt Fund CF 83.43K 0.13% ▲ 0.00% Apr 30, 2026
6 TD Health Sciences - I 80.33K 0.13% ▲ 0.00% Dec 31, 2025
7 SEI Small Cap II A (SIIT) 75.10K 0.12% ▲ 0.00% Apr 30, 2026
8 BlackRock Extended Equity Market Fund K 71.04K 0.11% ▲ 205.85% Mar 31, 2026
9 Bridgeway Ultra-Small Company Market 50.00K 0.08% ▲ 0.00% Mar 31, 2026
10 Fidelity Total Market Index 43.62K 0.07% ▲ 0.00% Mar 31, 2026

Valuation Metrics

Enterprise Value: $240.41M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $278.76M
EBITDA: $-81.17M
Book Value: $0.96
Earnings/Share: $-1.00
Profit Margin: 0.00%
Operating Margin: -309.54%
ROA (TTM): -39.69%
ROE (TTM): -95.25%
Revenue (TTM): $16.72M
Revenue/Share (TTM): $0.21
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 41.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 1.99x 0.04x 0.51x N/A -0.03x
2024-12-31 5.30x 0.02x 0.25x N/A -0.02x
2023-12-31 10.79x 0.01x 0.15x N/A -0.01x
2022-12-31 9.42x 0.01x 0.11x -93.31x -0.01x
2021-12-31 15.37x 0.01x 0.06x -55.73x -0.02x
2020-12-31 19.41x 0.00x 0.05x N/A 0.00x
2019-12-31 4.18x -0.01x 3.26x N/A -0.01x
2018-12-31 6.37x 0.00x 2.38x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about PRLD.US!